Thomas Gwise

1.0k total citations
24 papers, 316 citations indexed

About

Thomas Gwise is a scholar working on Statistics and Probability, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Thomas Gwise has authored 24 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Statistics and Probability, 9 papers in Economics and Econometrics and 8 papers in Cancer Research. Recurrent topics in Thomas Gwise's work include Statistical Methods in Clinical Trials (13 papers), Cancer Genomics and Diagnostics (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Thomas Gwise is often cited by papers focused on Statistical Methods in Clinical Trials (13 papers), Cancer Genomics and Diagnostics (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Thomas Gwise collaborates with scholars based in United States, Austria and Australia. Thomas Gwise's co-authors include Richard Pazdur, Marc R. Theoret, Paul G. Kluetz, Rajeshwari Sridhara, Vishal Bhatnagar, Laura L. Fernandes, Jonathon Vallejo, Bindu Kanapuru, Laleh Amiri‐Kordestani and Shenghui Tang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Thomas Gwise

21 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Gwise United States 10 100 96 76 56 56 24 316
Junshan Qiu United States 9 134 1.3× 124 1.3× 76 1.0× 23 0.4× 42 0.8× 22 422
Jonathon Vallejo United States 12 68 0.7× 309 3.2× 84 1.1× 72 1.3× 86 1.5× 31 530
Pierre Squifflet Belgium 12 42 0.4× 214 2.2× 85 1.1× 95 1.7× 71 1.3× 20 406
Gautier Paux France 9 64 0.6× 115 1.2× 27 0.4× 50 0.9× 41 0.7× 26 394
Gwynn Ison United States 9 71 0.7× 216 2.3× 13 0.2× 102 1.8× 65 1.2× 16 439
Kyung Mann Kim United States 10 99 1.0× 102 1.1× 17 0.2× 25 0.4× 110 2.0× 16 363
David Dejardin Belgium 13 143 1.4× 90 0.9× 312 4.1× 20 0.4× 25 0.4× 28 559
Monia Ezzalfani France 8 98 1.0× 84 0.9× 17 0.2× 58 1.0× 33 0.6× 21 231
Clare Lendrem United Kingdom 13 16 0.2× 43 0.4× 44 0.6× 74 1.3× 111 2.0× 29 364
Grace Hsu Canada 7 70 0.7× 78 0.8× 8 0.1× 64 1.1× 52 0.9× 13 277

Countries citing papers authored by Thomas Gwise

Since Specialization
Citations

This map shows the geographic impact of Thomas Gwise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Gwise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Gwise more than expected).

Fields of papers citing papers by Thomas Gwise

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Gwise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Gwise. The network helps show where Thomas Gwise may publish in the future.

Co-authorship network of co-authors of Thomas Gwise

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Gwise. A scholar is included among the top collaborators of Thomas Gwise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Gwise. Thomas Gwise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Philip, Haijun Ma, Revathi Ananthakrishnan, et al.. (2025). Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical Trials. Therapeutic Innovation & Regulatory Science. 59(6). 1495–1505.
2.
Kanapuru, Bindu, Laura L. Fernandes, Andrea Baines, et al.. (2023). Eligibility criteria and Enrollment of a Diverse Racial and Ethnic population in Multiple Myeloma Clinical Trials. Blood. 142(3). 235–243. 15 indexed citations
3.
Mushti, Sirisha L., Flora Mulkey, Thomas Gwise, et al.. (2023). Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”. Statistics in Biopharmaceutical Research. 15(2). 315–317.
4.
Pulte, Dianne, Laura L. Fernandes, Ashley Woods, et al.. (2023). FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity. Clinical Lymphoma Myeloma & Leukemia. 23(6). 463–470.e1. 6 indexed citations
5.
Zirkelbach, Jeanne Fourie, Mirat Shah, Jonathon Vallejo, et al.. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of Clinical Oncology. 40(30). 3489–3500. 97 indexed citations
6.
Kanapuru, Bindu, Laura L. Fernandes, Lola A. Fashoyin‐Aje, et al.. (2022). Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood Advances. 6(6). 1684–1691. 32 indexed citations
7.
Fashoyin‐Aje, Lola A., Aracelis Z. Torres, Laura L. Fernandes, et al.. (2022). Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data. Blood Cancer Journal. 12(4). 65–65. 9 indexed citations
8.
Fernandes, Laura L., et al.. (2021). Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement. Blood Cancer Journal. 11(8). 148–148. 20 indexed citations
9.
Wang, Xin, Flora Mulkey, Xin Gao, et al.. (2021). Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials. Statistics in Biopharmaceutical Research. 15(2). 300–309. 9 indexed citations
10.
Kim, Nina, Jonathon Vallejo, Thomas Gwise, et al.. (2021). Response Rate, Event-Free Survival (EFS) and Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): U.S. Food and Drug Administration (FDA) Patient-Level Analyses. Blood. 138(Supplement 1). 2604–2604. 2 indexed citations
11.
Sridhara, Rajeshwari, Qi Jiang, Richard Pazdur, et al.. (2021). Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research. 14(3). 353–357. 16 indexed citations
12.
Gwise, Thomas, Mark D. Rothmann, Hung Hung, et al.. (2021). Statement on P-values. Statistics in Biopharmaceutical Research. 13(1). 57–58. 1 indexed citations
13.
Sridhara, Rajeshwari, Qi Jiang, Richard Pazdur, et al.. (2021). Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research. 14(3). 349–352. 8 indexed citations
14.
King‐Kallimanis, Bellinda L., Virginia E. Kwitkowski, R. Angelo de Claro, et al.. (2020). FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease. Quality of Life Research. 29(7). 1903–1911. 16 indexed citations
15.
Fernandes, Laura L., Bindu Kanapuru, Thomas Gwise, et al.. (2020). FDA analysis: Impact of BMI on efficacy outcomes in multiple myeloma trials.. Journal of Clinical Oncology. 38(15_suppl). 8543–8543. 5 indexed citations
16.
Chang, Elaine, Yutao Gong, Chana Weinstock, et al.. (2020). FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.. Journal of Clinical Oncology. 38(15_suppl). 5081–5081.
17.
Casak, Sandra J., Steven J. Lemery, Jee Young Chung, et al.. (2018). FDA's Approval of the First Biosimilar to Bevacizumab. Clinical Cancer Research. 24(18). 4365–4370. 28 indexed citations
18.
He, Kun, Huanyu Chen, Thomas Gwise, et al.. (2016). Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study. Clinical Cancer Research. 22(21). 5167–5170. 8 indexed citations
19.
Tang, Rong, et al.. (2013). Evaluation of Heart Failure Biomarker Tests: A Survey of Statistical Considerations. Journal of Cardiovascular Translational Research. 6(4). 449–457. 9 indexed citations
20.
Gwise, Thomas, Feifang Hu, & Jianhua Hu. (2008). Optimal biased coins for two-arm clinical trials. Statistics and Its Interface. 1(1). 125–135. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junshan Qiu Breakdown of academic impact, for papers by Jonathon Vallejo Breakdown of academic impact, for papers by Pierre Squifflet Breakdown of academic impact, for papers by Gautier Paux Breakdown of academic impact, for papers by Gwynn Ison Breakdown of academic impact, for papers by Kyung Mann Kim Breakdown of academic impact, for papers by David Dejardin Breakdown of academic impact, for papers by Monia Ezzalfani Breakdown of academic impact, for papers by Clare Lendrem Breakdown of academic impact, for papers by Grace Hsu
Rankless by CCL
2026